HC Wainwright Has Bullish Estimate for CRVS Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share estimate for Corvus Pharmaceuticals to ($0.14), a slight improvement from the previous estimate of ($0.15).
• Corvus Pharmaceuticals' stock received various ratings recently, with Mizuho setting a price target of $11.00 and Oppenheimer raising its target to $17.00, indicating a positive market outlook.
• Corvus Pharmaceuticals experienced a recent stock price increase of 11.1%, with shares currently trading at $5.00, while it has a market cap of approximately $372.55 million.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - HC Wainwright increased their Q3 2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.15). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.

CRVS has been the topic of a number of other research reports. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, May 20th. Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Oppenheimer restated an "outperform" rating and issued a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, Corvus Pharmaceuticals presently has an average rating of "Buy" and an average price target of $15.00.

Corvus Pharmaceuticals Price Performance

CRVS stock traded down $0.1080 during midday trading on Thursday, hitting $5.2120. The stock had a trading volume of 216,842 shares, compared to its average volume of 806,811. The firm has a market cap of $388.37 million, a PE ratio of -5.17 and a beta of 0.42. Corvus Pharmaceuticals has a 12-month low of $2.54 and a 12-month high of $10.00. The company's 50-day moving average price is $4.29 and its 200 day moving average price is $4.03.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of large investors have recently made changes to their positions in CRVS. Sowell Financial Services LLC acquired a new position in shares of Corvus Pharmaceuticals in the 1st quarter valued at about $38,000. Virtus ETF Advisers LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter worth approximately $47,000. Police & Firemen s Retirement System of New Jersey bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $49,000. Sender Co & Partners Inc. bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $52,000. Finally, ProShare Advisors LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $54,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Insider Buying and Selling at Corvus Pharmaceuticals

In other news, Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction on Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the transaction, the director owned 7,165,006 shares in the company, valued at approximately $29,806,424.96. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 28.50% of the stock is currently owned by company insiders.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.